Gilead Sciences. has been granted a patent for compounds and pharmaceutical compositions aimed at treating or preventing autoimmune diseases and inflammatory conditions, specifically systemic and cutaneous lupus erythematosus. The patent includes methods for making and using these compounds. GlobalData’s report on Gilead Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Gilead Sciences, Peptide pharmacophores was a key innovation area identified from patents. Gilead Sciences's grant share as of July 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12070455B2 outlines a series of claims related to specific compounds and their applications in pharmaceutical compositions. The primary focus is on a compound that can be selected from a defined group, with multiple claims detailing variations of this compound. The patent also includes claims for pharmaceutical compositions that incorporate the compound, along with acceptable excipients or carriers. Notably, these compositions may further include additional therapeutic agents, particularly anti-malarial agents such as chloroquine and hydroxychloroquine.
Additionally, the patent describes methods for inhibiting the activity of toll-like receptors 7 and 8, which are implicated in various diseases and inflammatory conditions. The claims specify therapeutic approaches for treating disorders associated with elevated activity of these receptors, including systemic lupus erythematosus, cutaneous lupus erythematosus, and lupus nephritis. Furthermore, the patent encompasses methods for treating a range of inflammatory conditions, detailing specific diseases such as inflammatory bowel disease, rheumatoid arthritis, and Sjogren's syndrome. The claims also allow for the combination of the primary compound with other therapeutic agents, enhancing the potential for comprehensive treatment strategies.
To know more about GlobalData’s detailed insights on Gilead Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
